Duncan boy back to a 'normal 11-year-old's life' after clinical trial | Community
Bentley, diagnosed with B-ALL in 2019, was enrolled in a clinical trial using blinatumomab with chemotherapy, achieving remission and remaining disease-free. The trial, halted early due to clear benefits, showed 96% of standard-risk B-ALL patients remained relapse-free at three years with the combination therapy. Blinatumomab, a targeted therapy with fewer side effects, is now standard practice for standard-risk B-ALL.
Highlighted Terms
Related News
Bentley, diagnosed with B-ALL in 2019, was enrolled in a clinical trial using blinatumomab with chemotherapy, achieving remission and remaining disease-free. The trial, halted early due to clear benefits, showed 96% of standard-risk B-ALL patients remained relapse-free at three years with the combination therapy. Blinatumomab, a targeted therapy with fewer side effects, is now standard practice for standard-risk B-ALL.